Farallon Capital Management 13F: Adds $59M to IMVT Stake

Farallon Capital Management Boosts Immunovant Stake

Farallon Capital Management significantly expanded its investment footprint in Immunovant, Inc. IMVT, according to its latest Form 13F filing with the SEC covering holdings as of May 15, 2026. The fund is known for taking sizable, tactical positions across the healthcare and biotech sectors. This filing reflects portfolio adjustments made during the period and may not represent the firm's exact current position today.

Position Details for Farallon Capital Management

During the reporting period, Farallon Capital Management boosted its position in Immunovant by a striking 12783.3%. The fund added 1,534,000 shares to its prior holding of 12,000 shares. That brought its ending stake to 1,546,000 shares. The reported value of this growing holding reached approximately $59.5 million.

Stock Performance and Market Context

Immunovant shares trade at $38.53 on the NasdaqGS, resting comfortably above their 200-day moving average of $31.28. The stock has moved within a 52-week low of $14.86 and a 52-week high of $45.42. With a market capitalization near $7.68 billion, the biotech firm attracts steady institutional interest even as it continues clinical development.

Recent Insider Activity at Immunovant

Corporate insiders have also adjusted their personal holdings around recent trading sessions. On June 18, 2026, Chief Legal Officer Van Tuyl Christopher sold 2,634 shares of Immunovant stock. The transaction was executed at a price of $35.39 per share, totaling $93,217.26.

Analysts Set New Price Targets

Wall Street firms remain broadly optimistic about the biotechnology company's clinical pipeline. On June 30, 2026, Citigroup maintained its buy rating on the stock while raising its price target to $61.00 from $57.00. Later, on August 4, 2026, JP Morgan maintained an overweight rating and lifted its target to $50.00 from $47.00. Across the broader analyst community, 16 experts give the stock a consensus buy recommendation with a mean target price of $48.88.

Understanding Immunovant's Focus

Immunovant operates as a clinical-stage immunology company headquartered in Durham, North Carolina. The firm develops targeted antibody therapies aimed at treating various autoimmune conditions, including Graves' disease and myasthenia gravis. As a subsidiary of Roivant Sciences Ltd., the company focuses its research on neutralizing specific receptor pathways to help patients with severe immunological needs.

What to Watch at Immunovant, Inc.

Investors tracking Immunovant will look toward its next scheduled earnings report on November 9, 2026, to gauge pipeline progress and financial burn rates. Future SEC filings will also reveal whether institutional funds like Farallon maintain or adjust their expanded share counts in upcoming quarters.